Trial Profile
A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs EYS 606 (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis; Uveitis
- Focus Adverse reactions; First in man
- Sponsors Eyevensys
- 11 May 2022 According to an Eyevensys media release, the company held a successful meeting with principal investigators and they reviewed the data from this trial.
- 09 Mar 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.